Determinants of Treatment Delay in Drug-Resistant Tuberculosis Patients
DOI:
https://doi.org/10.29313/bcsms.v5i3.21658Keywords:
tuberculosis, drug resistant, treatment delay, determinantAbstract
Abstract. The incidence of drug-resistant (DR) tuberculosis (TB) is increasing worldwide. In Indonesia, DR-TB was 31,000 cases in 2024, also increasing compared to 28,000 cases in 2021. 78.2% of TB patients who were diagnosed with DR-TB experienced treatment delay of up to ten days. In addition, treatment delay in patients with DR-TB can increase risk of disease transmission, development of the disease into extensively DR-TB, and possibility of poor treatment outcomes. The aim of this study was to analyze determinants of treatment delay in DR-TB patients. This cross-sectional study was conducted at Abdoel Moeloek Regional General Hospital in Lampung Province, one of the referral hospitals for DR-TB in the province. The sample included all 20 DR-TB patients recorded in August 2025. Data was collected through interviews using a questionnaire, which then analyzed using chi-square test. The results showed no relationship between age, gender, education, occupation, income, comorbidities, distance, or cost to the hospital and treatment delay in DR-TB patients. However, the results revealed an association between loss to follow-up in previous treatments (p-value: 0.002; odds ratio [OR]: 8.182, 95% CI: 1.277–12.416), visiting to other health facilities after diagnosed as TB-RO (p-value: 0.027; OR: 8.182, 95% CI: 2,0 (1,67 – 2,38) and treatment delay in DR-TB patients. Loss to follow up in previous TB treatment related to low motivation of TB patients to take medical treatment. This not only encourages TB patients to fail in first-line treatment, but it also impacts treatment delay when they are DR-TB patients. Visiting other health facilities rather than DR-TB hospital directly will also prolong treatment delay. In conclusion, a strategy is needed to manage TB patients who are lost to follow-up and visiting other health services to avoid increasing the burden on DR-TB patients.
References
2. World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023.
3. World Health Organization. Global Tuberculosis Report 2021. Geneva: WHO; 2021.
4. Kementerian Kesehatan Indonesia. Laporan Program Penanggulangan Tuberkulosis Tahun 2022. Kemenkes RI [Internet]. 2023;1–147. Available from: https://tbindonesia.or.id/pustaka_tbc/laporan-tahunan-program-tbc-2021/
5. Dirjen Pengendalian dan Pencegahan Penyakit Kementrian Kesehatan RI. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resisten Obat di Indonesia. Jakarta: Kementrian Kesehatan RI; 2020. 240 p.
6. Menteri Kesehatan RI. Keputusan Menteri Kesehatan RI No. HK 01.07/Menkes/350/2017 tentang Rumah Sakit dan Balai Kesehatan Pelaksana Layanan Tuberkulosis Resisten Obat. Indonesia; 2017 p. 20.
7. Noman MZI, Islam S, Aktar S, Parray AA, Amando DG, Karki J, et al. Healthcare seeking behavior and delays in case of Drug-Resistant Tuberculosis patients in Bangladesh: Findings from a cross-sectional survey. PLOS Glob Public Heal. 2024;4:1–22.
8. Akalu TY, Clements ACA, Gebreyohannes EA, Xu Z, Bai L, Alene KA. Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China. BMC Infect Dis. 2024;24(1):1–11. https://doi.org/10.1186/s12879-024-09036-2
9. Akalu TY, Clements ACA, Xu Z, Bai L, Alene KA. Predictors of poor treatment outcomes among drug-resistant tuberculosis patients in Hunan province, China. Heliyon [Internet]. 2024;10(23):e40391. https://doi.org/10.1016/j.heliyon.2024.e40391
10. Kasozi ND, Charles L, JohnBosco A, Henry L. Predictors of treatment delay among drug resistant tuberculosis patients in Uganda. BMC Infect Dis. 2024;24(1). https://doi.org/10.1186/s12879-024-10339-7
11. Lestari BW, Nijman G, Larasmanah A, Soeroto AY, Santoso P, Alisjahbana B, et al. Management of drug-resistant tuberculosis in Indonesia: a four-year cascade of care analysis. Lancet Reg Heal - Southeast Asia. 2024;22(38):100294. https://doi.org/10.1016/j.lansea.2023.100294
12. Lönnroth K. Risk Factors and Social Determinants of TB. The Union NAR Meeting 24 Feb 2011 [Internet]. 2011. Available from: http://www.bc.lung.ca/association_and_services/documents/KnutUnionNARTBriskfactorsanddeterminantsFeb2011.pdf
13. Lestari BW, McAllister S, Hadisoemarto PF, Afifah N, Jani ID, Murray M, et al. Patient pathways and delays to diagnosis and treatment of tuberculosis in an urban setting in Indonesia. Lancet Reg Heal - West Pacific. 2020;5:100059. https://doi.org/10.1016/j.lanwpc.2020.100059
14. Silitonga P, Jiang W, Wyatt S, Burhan E, Kes EFM, Long Q. Factors affecting time to treatment initiation after diagnosis for multidrug-resistant/rifampicin-resistant tuberculosis patients: A mixed-methods study in Jakarta, Indonesia. Trop Med Int Heal. 2023;28(1):43–52.
15. Rima DD, Legese D, Woldesemayat EM. Tuberculosis treatment delay and associated factors among pulmonary tuberculosis patients at public health facilities in Dale District and Yirgalem Town administration, Sidama Region, South Ethiopia. BMC Infect Dis. 2024;24(1):1–9.
16. Sharifov R, Nabirova D, Tilloeva Z, Zikriyarova S, Kishore N, Jafarov N, et al. TB treatment delays and associated risk factors in Dushanbe, Tajikistan, 2019–2021. BMC Infect Dis. 2024;24(1).
17. Dinas Kesehatan Provinsi Lampung. Drug-resistant Tuberculosis in Lampung Province: 2023 Report. Bandar Lampung; 2023.
18. Dinas Kesehatan Provinsi Lampung. Drug-resistant Tuberculosis in Lampung Province: 2022 Report. Bandar Lampung; 2022.
19. Lampung Province Health Office. Drug-resistant Tuberculosis in Lampung Province: 2023 Report. Bandar Lampung; 2024.
20. Wardani DWSR, Wahono EP. Predominant Determinants of Delayed Tuberculosis Sputum Conversion in Indonesia. Indian J Community Med. 2019;44(1):53–7.
